Immunome, Inc.

Stage 3 · Topping · week 3

As of Oct 22, 2026, Immunome is in Stage 3, the topping phase, now in week 3 (since Oct 8, 2026). It closed at $18.26, 38.8% below its 52-week high and below its 200-day average, which is falling.

$18.26

+1.44% today

$2.2B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is IMNM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 28w

S4 35w

S2 32w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 5w → S3 3w → S2 28w → S3 9w → S4 9w → S1 5w → S4 35w → S1 10w → S2 32w → S3 6w → S2 4w → S3 7w → S2 10w → S3 2w current

Total tracked: 165 weeks across 14 stage runs.

IMNM among Biotechnology155th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…155	IMNMImmunome, Inc.	Stage 3 · wk 3	62	−24.7%

vs 52W High

-38.8%

$15.24 lo$29.83 hi

38.8% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 3

1w13w26w

Week 3, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-19.1%

200 DMA: $22.56 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

1.34x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-24.7%

-17.8%

-20.6%

YTD

-12.3%

+9.1%

Scan Membership

Breakout Watch

Latest: 2023-10-16

4 appearances in last 60 days. First seen: 2022-10-27.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 3 · Vol 1.34x

2026-10-21S3

Wk 2 · Vol 0.97x

2026-10-20S3

Wk 2 · Vol 1.57x

2026-10-19S3

Wk 2 · Vol 0.89x

2026-10-16S3

Wk 2 · Vol 1.02x

2026-10-15S3

Wk 2 · Vol 1.28x

2026-10-14S3

Wk 1 · Vol 0.90x

2026-10-13S3

Wk 1 · Vol 1.73x

2026-10-12S3

Wk 1 · Vol 0.66x

2026-10-09S3

Wk 1 · Vol 0.79x

2026-10-08S32→3

Wk 1 · Vol 1.73x

2026-10-07S2

Wk 10 · Vol 0.95x

Moving averages & range

50 DMA

$23.57

200 DMA

$22.56

52W High

$29.83

52W Low

$15.24

5D Low

$16.47

Resistance levels (recent highs)

20d High

$21.89

60d High

$29.83

120d High

$29.83

250d High

$29.83

Next resistance

+19.9%

to 20d High

ROE

-64.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 3.9

Immunome: quick answers

What stage is Immunome in?

As of Oct 22, 2026, Immunome (IMNM) is in Stage 3, the topping phase. It entered Stage 3 on Oct 8, 2026 and is in week 3. What the four stages mean

Is Immunome in an uptrend?

Its uptrend has stalled. Immunome is in Stage 3, the topping phase that follows an advance. It trades 19.1% below its 200-day average, which is falling.

How far is Immunome from its 52-week high?

Immunome closed at $18.26 on Oct 22, 2026, 38.8% below its 52-week high of $29.83. Its 52-week low is $15.24.

How has Immunome performed over the past year?

As of Oct 22, 2026, Immunome is up 9.1% over the past year and down 12.3% so far in 2026.

Which sector and industry is Immunome in?

Immunome is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.